Rating Change
Freedom Broker reiterated its Buy rating on INmune Bio, Inc. (NASDAQ:INMB) on November 13, 2026.
Freedom Broker reiterated its Buy rating on INmune Bio, Inc. (NASDAQ:INMB) on November 13, 2026.

At publication ·
INmune Bio, Inc. (NASDAQ:INMB) · reiterate
At a glance
Freedom Broker reiterated its Buy rating on INmune Bio, Inc. (NASDAQ:INMB) on November 13, 2026.
INmune Bio, Inc. operates in the Healthcare sector. The stock currently trades at $1.05 with a market capitalization of $56.6M.
Analyst coverage from Freedom Broker provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for INmune Bio, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 8 Buy, 1 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 13, 2026 | Freedom Broker | Buy | N/A |
| Mar 11, 2026 | LUCID CAPITAL MARKETS | Buy | N/A |
| Jul 02, 2025 | Maxim Group | Buy | N/A |
| Jul 01, 2025 | BTIG | Neutral | N/A |
| Jul 01, 2025 | Scotiabank | Sector Underperform | N/A |
Related Tools: Analyst Ratings Dashboard | View INMB Stock Page
A rating of Buy from Freedom Broker reflects the analyst's outlook on INmune Bio, Inc. (NASDAQ:INMB). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the INMB forecast page.
Current market data
NASDAQ · INMB
$1.03
Down: -$0.14 · -13.19%
Live quote updated
Keep reading